Identification of 4‐Anilinoquin(az)oline as a Cell‐Active Protein Kinase Novel 3 (PKN3) Inhibitor Chemotype**
- 9 May 2022
- journal article
- research article
- Published by Wiley in ChemMedChem
- Vol. 17 (12) , e202200161
Abstract
Deep annotation of a library of 4‐anilinoquin(az)olines led to the identification of 7‐iodo‐N‐(3,4,5‐trimethoxyphenyl)quinolin‐4‐amine 16 as a potent inhibitor (IC50=14 nM) of Protein Kinase Novel 3 (PKN3) with micromolar activity in cells. Compound 16 is a potential tool compound to study the cell biology of PKN3 and its role in pancreatic and prostate cancer and T‐cell acute lymphoblastic leukemia. These 4‐anilinoquin(az)olines may also be useful tools to uncover the therapeutic potential of PKN3 inhibition in a broad range of diseases.Keywords
Funding Information
- Canada Foundation for Innovation (1097737)
- Innovative Medicines Initiative (115766)
- National Institutes of Health (1U24DK116204-01)
- University of North Carolina at Chapel Hill (CHE-1726291)
This publication has 55 references indexed in Scilit:
- Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast CancerCell, 2012
- Testing the Promiscuity of Commercial Kinase Inhibitors Against the AGC Kinase Group Using a Split-luciferase ScreenJournal of Medicinal Chemistry, 2012
- Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivityNature Biotechnology, 2011
- Application of a split luciferase complementation assay for the detection of viral protein–protein interactionsJournal of Virological Methods, 2011
- A Coiled-Coil Enabled Split-Luciferase Three-Hybrid System: Applied Toward Profiling Inhibitors of Protein KinasesJournal of the American Chemical Society, 2010
- Development of an intracellularly acting inhibitory peptide selective for PKNBiochemical Journal, 2009
- High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemiaBlood, 2009
- The challenge of selecting protein kinase assays for lead discovery optimizationExpert Opinion on Drug Discovery, 2008
- RNAi therapeutics: Principles, prospects and challengesAdvanced Drug Delivery Reviews, 2007
- A small molecule–kinase interaction map for clinical kinase inhibitorsNature Biotechnology, 2005